Article Information
History
- July 10, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Anupriya Aggarwal1,*,
- Anouschka Akerman1,*,
- Vanessa Milogiannakis1,*,
- Mariana Ruiz Silva,
- Gregory Walker2,
- Andrea Kidinger1,
- Thomas Angelovich3,
- Emily Waring3,
- Supavadee Amatayakul-Chantler4,
- Nathan Roth4,
- Germano Coppola4,
- Malinna Yeang2,
- Tyra Jean2,
- Charles Foster2,
- Alexandra Carey Hoppe1,
- C. Mee Ling Munier1,
- David Darley5,
- Melissa Churchill3,
- Damian Starck6,
- Daniel Christ7,
- Gail Matthews1,5,
- William Rawlinson2,
- Anthony D. Kelleher1,5 and
- Stuart Turville1,#
- 1The Kirby Institute, University of New South Wales, New South Wales, Australia
- 2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
- 3School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
- 4Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland
- 5St Vincent’s Hospital, Sydney, New South Wales, Australia
- 6Molecular Diagnostic Medicine Laboratory, Sydpath, St Vincent’s Hospital, Sydney, New South Wales, Australia
- 7Garvan Institute of Medical Research, Sydney, New South Wales, Australia
- ↵#Corresponding Author: Stuart G. Turville, The Kirby Institute, UNSW Australia, Office 529 Level 5 Wallace Wurth Building, UNSW, Sydney NSW 2052, Telephone: +61 (02) 9385 0462, Email: sturville{at}kirby.unsw.edu.au
↵* Equal contribution
Posted July 10, 2022.
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
